Advertisement
UK markets close in 6 hours 43 minutes

  • FTSE 100

    8,108.18
    +29.32 (+0.36%)
     

  • FTSE 250

    19,810.11
    +208.13 (+1.06%)
     

  • AIM

    755.86
    +2.74 (+0.36%)
     

  • GBP/EUR

    1.1661
    +0.0004 (+0.04%)
     

  • GBP/USD

    1.2533
    +0.0022 (+0.17%)
     

  • Bitcoin GBP

    51,387.82
    +474.51 (+0.93%)
     

  • CMC Crypto 200

    1,389.15
    -7.38 (-0.53%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    83.77
    +0.20 (+0.24%)
     

  • GOLD FUTURES

    2,359.90
    +17.40 (+0.74%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,055.73
    +138.45 (+0.77%)
     

  • CAC 40

    8,044.47
    +27.82 (+0.35%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

BUZZ-Indivior: Citi tips spinoff to outperform parent

Reuters - UK Focus

** Indivior (Other OTC: INVVY - news) initiated at "Buy" by Citi, expects co to outperform former parent Reckitt Benckiser (Xetra: A0M1W6 - news)

** High risk/reward: says market pricing in high probability (> 90 pct) of negative litigation outcome on main product Suboxone (c. 75 pct revenues)

** Citi says any impact unlikely to be felt until 2019, allowing co time to replace lost revenues

** Pharma demergers (Abbvie (Xetra: 4AB.DE - news) , Zoetis (NYSE: ZTS - news) , Mead Johnson ) tend to outperform parents, bank points out. Chart on pharma demergers: http://link.reuters.com/vek73w

** Citi values stock at 10.2x 2016 earnings, below peer group figure of 19.4, according to Thomson Reuters data

** Reckitt Benckiser up 1.6 pct

(RM (LSE: RM.L - news) : alasdair.pal.thomsonreuters.com@reuters.net)